Cited 0 times in
A Prospective Study of Preemptive Tenofovir Disoproxil Fumarate Therapy in HBsAg-Positive Patients With Diffuse Large B-Cell Lymphoma Receiving Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김도영 | - |
dc.contributor.author | 김유리 | - |
dc.contributor.author | 김진석 | - |
dc.contributor.author | 현신영 | - |
dc.date.accessioned | 2023-10-19T05:45:17Z | - |
dc.date.available | 2023-10-19T05:45:17Z | - |
dc.date.issued | 2023-08 | - |
dc.identifier.issn | 0002-9270 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/196263 | - |
dc.description.abstract | Introduction: This prospective study aimed to investigate the efficacy and safety of preemptive antiviral therapy with tenofovir disoproxil fumarate (TDF) for HBsAg-positive patients with newly diagnosed diffuse large B-cell lymphoma receiving rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy. Methods: We enrolled 73 patients from 20 institutions. The primary end point was the absolute risk of hepatitis B virus (HBV)-related hepatitis during preemptive TDF therapy and for 24 weeks after withdrawal from TDF. Hepatitis was defined as a more than 3-fold increase in serum alanine aminotransferase from baseline or an alanine aminotransferase level of ≥100 U/L. HBV-related hepatitis was defined as hepatitis with an increase in serum HBV-DNA to >10 times that of the pre-exacerbation baseline or an absolute increase of ≥20,000 IU/mL compared with the baseline. Results: No patient developed HBV reactivation or HBV-related hepatitis during preemptive antiviral therapy (until 48 weeks after completion of R-CHOP chemotherapy) with TDF. All adverse events were grade 1 or 2. HBV reactivation was reported in 17 (23.3%) patients. All HBV reactivation was developed at a median of 90 days after withdrawal from TDF (range, 37-214 days). Six (8.2%) patients developed HBV-related hepatitis at a median of 88 days after withdrawal from TDF (range, 37-183 days). Discussion: Preemptive TDF therapy in HBsAg-positive patients with diffuse large B-cell lymphoma receiving R-CHOP chemotherapy was safe and effective for preventing HBV-related hepatitis. However, a long-term maintenance strategy of preemptive TDF therapy should be recommended because of the relatively high rate of HBV-related hepatitis after withdrawal from TDF ( ClinicalTrials.gov ID: NCT02354846). Copyright © 2023 by The American College of Gastroenterology. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Nature Pub. Group | - |
dc.relation.isPartOf | AMERICAN JOURNAL OF GASTROENTEROLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Alanine Transaminase | - |
dc.subject.MESH | Antiviral Agents / therapeutic use | - |
dc.subject.MESH | Cyclophosphamide / therapeutic use | - |
dc.subject.MESH | DNA, Viral | - |
dc.subject.MESH | Doxorubicin / therapeutic use | - |
dc.subject.MESH | Hepatitis B Surface Antigens | - |
dc.subject.MESH | Hepatitis B virus | - |
dc.subject.MESH | Hepatitis B, Chronic* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lymphoma, Large B-Cell, Diffuse* / chemically induced | - |
dc.subject.MESH | Lymphoma, Large B-Cell, Diffuse* / drug therapy | - |
dc.subject.MESH | Prednisone / therapeutic use | - |
dc.subject.MESH | Prospective Studies | - |
dc.subject.MESH | Rituximab / adverse effects | - |
dc.subject.MESH | Tenofovir / adverse effects | - |
dc.subject.MESH | Vincristine / adverse effects | - |
dc.title | A Prospective Study of Preemptive Tenofovir Disoproxil Fumarate Therapy in HBsAg-Positive Patients With Diffuse Large B-Cell Lymphoma Receiving Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Do Young Kim | - |
dc.contributor.googleauthor | Yu Ri Kim | - |
dc.contributor.googleauthor | Cheolwon Suh | - |
dc.contributor.googleauthor | Dok Hyun Yoon | - |
dc.contributor.googleauthor | Deok-Hwan Yang | - |
dc.contributor.googleauthor | Yong Park | - |
dc.contributor.googleauthor | Hyeon Seok Eom | - |
dc.contributor.googleauthor | Jeong-Ok Lee | - |
dc.contributor.googleauthor | Jae-Yong Kwak | - |
dc.contributor.googleauthor | Hye Jin Kang | - |
dc.contributor.googleauthor | Shin Young Hyun | - |
dc.contributor.googleauthor | Jae-Cheol Jo | - |
dc.contributor.googleauthor | Myung Hee Chang | - |
dc.contributor.googleauthor | Kwai Han Yoo | - |
dc.contributor.googleauthor | Sung-Nam Lim | - |
dc.contributor.googleauthor | Ho-Jin Shin | - |
dc.contributor.googleauthor | Won Seog Kim | - |
dc.contributor.googleauthor | In-Ho Kim | - |
dc.contributor.googleauthor | Min Kyung Kim | - |
dc.contributor.googleauthor | Hyo Jung Kim | - |
dc.contributor.googleauthor | Won-Sik Lee | - |
dc.contributor.googleauthor | Yeung-Chul Mun | - |
dc.contributor.googleauthor | Jin Seok Kim | - |
dc.identifier.doi | 10.14309/ajg.0000000000002185 | - |
dc.contributor.localId | A00385 | - |
dc.contributor.localId | A00779 | - |
dc.contributor.localId | A01017 | - |
dc.contributor.localId | A04381 | - |
dc.relation.journalcode | J00081 | - |
dc.identifier.eissn | 1572-0241 | - |
dc.identifier.pmid | 36728217 | - |
dc.identifier.url | https://journals.lww.com/ajg/fulltext/2023/08000/a_prospective_study_of_preemptive_tenofovir.18.aspx | - |
dc.contributor.alternativeName | Kim, Do Young | - |
dc.contributor.affiliatedAuthor | 김도영 | - |
dc.contributor.affiliatedAuthor | 김유리 | - |
dc.contributor.affiliatedAuthor | 김진석 | - |
dc.contributor.affiliatedAuthor | 현신영 | - |
dc.citation.volume | 118 | - |
dc.citation.number | 8 | - |
dc.citation.startPage | 1373 | - |
dc.citation.endPage | 1380 | - |
dc.identifier.bibliographicCitation | AMERICAN JOURNAL OF GASTROENTEROLOGY, Vol.118(8) : 1373-1380, 2023-08 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.